Introdução: Estimulação transcraniana com corrente contínua (ETCC) é um método não invasivo de estimulação cerebral que modifica o potencial de repouso da membrana neuronal através de uma corrente elétrica de baixa intensidade. Trata-se de uma técnica neuromodulatória aplicável ao contexto terapêutico de disfunções do sistema nervoso implicados na fisiopatologia da dor e transtornos neuropsiquiátricos, com baixo custo, mínimos efeitos adversos e fácil aplicação. A ETCC tem se mostrado eficaz no tratamento de dores crônicas incluindo a fibromialgia (FM) em curto prazo. Seu uso se sustenta na melhor compreensão dos mecanismos fisiopatológicos dessa síndrome, os quais incluem processos de desinibição em nível cortical e infracortical, demonstrado por medidas neurofisiológicas como facilitação e desinibição, assim como redução da potência dos sistemas modulatórios descendentes da dor, além de alterações nas vias nociceptivas periféricas, como as fibras nervosas finas. No entanto, essa alteração isolada não foi previamente associada à disfunção no sistema de modulação descendente da dor (SMDD), observado na FM. As áreas de aplicação da ETCC dependem do objetivo terapêutico. O córtex motor primário (M1) é o alvo mais estudado e com maior contingente de evidências para o tratamento da dor e reabilitação motora, enquanto o córtex pré-frontal dorsolateral esquerdo (DLPFC) tem sido eficaz na depressão e melhora dos componentes psicoafetivos dos pacientes com dor crônica. Seu principal limitador prático é a necessidade de ir ao centro de atendimento durante dias consecutivos, pois o efeito terapêutico sustentado da ETCC necessita repetição das sessões Objetivos: Esta tese está constituída por dois estudos. O primeiro objetiva examinar se a disfunção de fibras finas que ocorre em pacientes com FM está ligada a um mau funcionamento do sistema modulador descendente da dor. No segundo, o objetivo é avaliar a eficácia do uso em longo prazo da ETCC em nível domiciliar na FM, com o objetivo de facilitar o uso e permitir a disponibilização desta técnica a pacientes do Sistema Único de Saúde. Estudo I: No primeiro estudo avaliamos se a disfunção de fibras nervosas finas periféricas está ligada a um mau funcionamento do sistema modulador descendente da dor (SMD) na FM. Métodos: Foi realizado um estudo exploratório no qual 41 mulheres com FM e 28 voluntárias saudáveis foram submetidas a testes psicofísicos que avaliaram a função de fibras sensitivas envolvidas na nocicepção. O teste quantitativo sensorial (QST) foi utilizado para medir o limiar perceptivo térmico (HTT), o limiar de dor térmica (HPT) e o limiar de tolerância à dor térmica (HPTo), bem como avaliar a mudança na Escala Numérica de Dor (NPS0-10) durante uma tarefa de modulação da dor condicionada (CPM-task). A algometria foi utilizada para determinar o limiar de pressão de dor (PPT). Escalas para avaliação de catastrofização, ansiedade, depressão e distúrbios do sono também foram aplicadas. O fator neurotrófico derivado do cérebro (BDNF) foi medido como um marcador de neuroplasticidade. Realizamos modelos de regressão linear multivariada por grupo (saudáveis e FM) para estudar a relação entre a função do SMD e sua relação com as medidas psicofísicas. Resultados: As amostras diferiram em seu perfil psicológico, e nas medidas psicofísicas, o grupo e pacientes com FM apresentou menor sensibilidade e limiares de dor. Na FM, mas não nos saudáveis, os modelos de regressão revelaram que o HTT estava relacionado ao BDNF e ao CPM-Task (Hotelling's Trace = 1,80, P<0,001, poder=0,94, R2=0,64). HTT foi correlacionado positivamente com a CPM-task (B = 0,98, P= 0,004, Partial-ƞ2=0,25), e ao HPT (B=1,61, P=0,008, parcial -ƞ2= 0,21). No entanto PPT não foi correlacionado com o HTT. Na FM a relação do BDNF com CPM-Task teve uma relação negativa (B=-0,04, P=0,043, parcial-ƞ2=0,12) e a HPT foi diretamente proporcional (B= - 0,08, P=0,03, parcial-ƞ2 = 0,14). O BDNF não influenciou no modelo. E os efeitos adversos relatados foram maiores no grupo ativo (17,8%) em comparação com o grupo sham (6,6%). Conclusão: A disfunção sensorial periférica está associada positivamente à disfunção do sistema modulatório descendente da dor e aos níveis séricos de BDNF na FM, o que não ocorre em indivíduos saudáveis. Estudo II: O segundo estudo teve como objetivo avaliar a eficácia do uso domiciliar de 60 sessões da ETCC-ativa e ETCC-simulada aplicadas sobre a área DLPFC esquerda, nas pacientes com diagnóstico de FM. Métodos: Foi realizado um ensaio clínico randomizado, duplo cego, em paralelo, controlado com ETCC-simulada em 20 mulheres com diagnóstico de fibromialgia. A estimulação foi realizada durante cinco dias consecutivos na semana, durante 30 min, com a intensidade de 2 mA, por 12 semanas, totalizando 60 sessões. As pacientes receberam treinamento para uso do equipamento especialmente desenvolvido para uso domiciliar e mantinham contato com o pesquisador responsável por meio de mensagem de texto diariamente. Os efeitos foram medidos por meio da escala visual de dor (EAV) durante o curso de 12 semanas de tratamento, bem como o uso de analgésicos e possíveis eventos adversos, diariamente. Foram avaliados os níveis de depressão, catastrofismo e capacidade funcional para tarefas diárias, QST para verificar limiar de dor e tolerância ao calor, PPT e dosagem dos níveis séricos de BDNF no início, após 30 sessões e no final do tratamento. Um modelo linear misto com efeitos fixos foi usado para comparar mudanças nos escores de dor na EAV ao longo do tratamento. Resultados: A ETCC ativa domiciliar reduziu os escores de dor pela EAV (p<0.001) quando comparado ao sham, com uma redução média de dor de 64% (p<0.001). Além disso, ETCC ativa reduziu significativamente a incapacidade relacionada a dor [B-PCP:S escore total (p=0.023);-ƞ2=0.61]. Também reduziu os escores nas medidas clínicas de depressão, catastrofismo e qualidade do sono [BDI-II, PCS e PSQI (p<0.05)]. No entanto, ETCC ativa aumentou os escores na algometria (PPT) e tolerância térmica (HPTo) (p<0.01). O BDNF não influenciou no modelo. Os efeitos adversos relatados foram maiores no grupo ativo (17,8%) em comparação com o grupo sham (6,6%). Conclusão: A ETCC para uso domiciliar mostrou-se segura e eficaz na redução da dor, incapacidade relacionada a dor, sintomas depressivos e catastróficos e redução do uso de analgésicos. O conjunto de dados desta tese sugere que em pacientes fibromiálgicas, o nível de disfunção do sistema modulador descendente da dor está relacionado ao nível de disfunção de fibras nervosas finas periféricas envolvidas na nocicepção. Além disso, a ETCC de longo prazo em fibromiálgicas foi eficaz na melhora dos sintomas disfuncionais relacionados à dor crônica e se mostrou adequada para uso domiciliar. / Introduction: Transcranial direct current stimulation (tDCS) is a noninvasive method of brain stimulation that modifies the resting potential of the neuronal membrane through a low intensity electrical current. It is a neuromodulatory technique to the therapeutic context of dysfunctions of the nervous system implicit in physiotherapy and neuropsychological disorders, with low cost, adverse effects and easy application. tDCS has been effective without a chronic fight process, including fibromyalgia (FM), in which the processes of disinhibition are cortical and infracortical, demonstrated by neurophysiological as intracortical facilitation and desinhibition, as well as reduction of the power of the systems descending pain modulators. In addition, studies have shown a severity of inhibition of central positive correlation with BDNF (Brain Derived Neurotrophic Factor) levels and seems to have some relation to the peripheral nociceptive pathways, as the areas of application of the stimulation depend on the primary motor cortex (M1) is the most studied target and the largest contingent of selection for the treatment of pain and motor reaction, while the dorsolateral prefrontal cortex (DLPFC) was effective in the treatment of depression and psychoaffective components in cases of patients with the chronic condition. Although tDCS has been successful in treating FM, its main limiter is a need for the service center for consecutive days as it has cumulative effect. In fact, the erasure of the sessions guaranteed the therapeutic effect of the ETCC. The application of measures on consecutive days motivated the study of its value when applied at the household level, in order to allow the large-scale treatment technique to be adopted in the Unified Health System. This is proved by two studies. The first objective is to examine whether a fine-fiber dysfunction that occurs in patients with FM is linked to an operation of the pain-modulating system. Neuropathy of long nerve fibers has been implicated by a descriptor of pain, neurophysiological and psychophysiological neurophysiology, as well as skin biopsy studies. However, this comparison was not associated with dysfunction in the descending pain system (DPMS) not on FM. Objective did the study explore the association of dysfunction of small fibers with the DPMS and other substitutes for nociceptive changes in FM. In the second, the term is a measure of long-term use of ETCC at household level in FM Study I: In this first study evaluating the presence of nerve and peripheral fiber failure, it is linked to the functioning of the descending pain modulator system (DPMS) in FM Methods: It was performed an exploratory study with 41 FM women and 28 healthy volunteers whose were evaluated in psychophysical tests that evaluated a function of sensory fibers involved in nociception. The quantitative sensory test (QST) was used to measure the Heat thermal threshold (HTT), the heat pain threshold (HPT) and the thermal pain tolerance (HPTo), as well as the numerical scale of pain (NPS0 -10 ) over a task of modulation of conditioned pain (CPM-task). Algometry was used to determine the pain pressure threshold (PPT). Scales for evaluation of catastrophic, anxiety, depression and sleep disorders were also applied. Brain-derived neurotrophic factor (BDNF) was measured as a marker of neuroplasticity. Multivariate linear regression models by group (health and FM) for a relationship between a descending modulatory system function and its relationship with psychophysical measures. Results: The samples differed in their psychological profile, and in the psychophysical measures, the group and the patients with FM had lower sensitivity and pain thresholds. At FM, regression models revealed that HTT was related to BDNF and CPM-Task (Hotelling's Trace = 1.80, P <0.001, power = 0.94, R2 = 0.64). HTT was positively correlated with a CPM task (B = 0.98, P = 0.004, partial-ƞ2 = 0.25), and HPT (B = 1.61, P = 0.008, partial -ƞ2 = 0.21) . However PPT was not correlated with HTT. In FM, the relationship of BDNF with CPM, a negative relation was found (B = -0.04, P = 0.043, partial- = 2 = 0.12) and HPT was proportionally (B = -0.08, P = 0.03, partial-ƞ2 = 0.14). BDNF did not influence the model. And the adverse effects reported were higher in the active group (17.8%) compared to the sham group (6.6%). Conclusion: Peripheral sensory dysfunction is positively associated with the modulating dysfunction of BDNF levels in FM, which does not occur in isolated individuals. Study II: The second study had the purpose of evaluating the home use of 60 sessions of atDCS and s-tDCS on a left DLPFC area in patients with FM. Methods: A randomized, double-blind, parallel-sham controlled study in 20 women with FM. Stimulation was performed for five consecutive days in the week for 30 min at the intensity of 2 mA for 12 weeks, totaling 60 sessions. Patients were trained to use equipment specially designed for home use and maintained contact with the researcher responsible through daily text message. The effects were measured through visual pain scale (VAS) daily during the course of 12 weeks of treatment, as well as the use of analgesics and possible adverse events daily. The levels of depression, catastrophism and disability for daily tasks were assessed. The QST was used to check pain threshold and tolerance to heat, an algometry was used to check pressure pain threshold (PPT) and blood collection was performed to evaluate serum BDNF levels at baseline, after 30 sessions and at the end of treatment. A Mixed Linear Model with fixed effects was used to compare changes in pain scores in VAS throughout the treatment. Results: Home-based tDCS reduced dairy pain VAS scores (p<0.001), with cumulative mean pain drop of 64% (p<0.001). Furthermore, active home-based tDCS reduced significantly disability due to pain [B-PCP:S total scores (p=0.023; partial-ƞ2=0.61]. And also reduced scores in clinical measures like depression scores, catastrophizing pain scores and sleep quality scores [BDI-II and PCS (p<0.05), PSQI (p<0.05)]. However, active homebased tDCS enhance scores in algometry (PPT) and heat pain tolerance (HPTo) (p<0.01). Conclusion: Home-based anodal tDCS applied over the DLPFC in FM had a baseline neuroplasticity-dependent reduction effect on pain. In addition, it improved the disability due to pain, depressive symptoms and pain catastrophizing. It reduced the analgesic use and increased pressure and heat pain tolerance.

Introdução: Estimulação transcraniana com corrente contínua (ETCC) é um método não invasivo de estimulação cerebral que modifica o potencial de repouso da membrana neuronal através de uma corrente elétrica de baixa intensidade. Trata-se de uma técnica neuromodulatória aplicável ao contexto terapêutico de disfunções do sistema nervoso implicados na fisiopatologia da dor e transtornos neuropsiquiátricos, com baixo custo, mínimos efeitos adversos e fácil aplicação. A ETCC tem se mostrado eficaz no tratamento de dores crônicas incluindo a fibromialgia (FM) em curto prazo. Seu uso se sustenta na melhor compreensão dos mecanismos fisiopatológicos dessa síndrome, os quais incluem processos de desinibição em nível cortical e infracortical, demonstrado por medidas neurofisiológicas como facilitação e desinibição, assim como redução da potência dos sistemas modulatórios descendentes da dor, além de alterações nas vias nociceptivas periféricas, como as fibras nervosas finas. No entanto, essa alteração isolada não foi previamente associada à disfunção no sistema de modulação descendente da dor (SMDD), observado na FM. As áreas de aplicação da ETCC dependem do objetivo terapêutico. O córtex motor primário (M1) é o alvo mais estudado e com maior contingente de evidências para o tratamento da dor e reabilitação motora, enquanto o córtex pré-frontal dorsolateral esquerdo (DLPFC) tem sido eficaz na depressão e melhora dos componentes psicoafetivos dos pacientes com dor crônica. Seu principal limitador prático é a necessidade de ir ao centro de atendimento durante dias consecutivos, pois o efeito terapêutico sustentado da ETCC necessita repetição das sessões Objetivos: Esta tese está constituída por dois estudos. O primeiro objetiva examinar se a disfunção de fibras finas que ocorre em pacientes com FM está ligada a um mau funcionamento do sistema modulador descendente da dor. No segundo, o objetivo é avaliar a eficácia do uso em longo prazo da ETCC em nível domiciliar na FM, com o objetivo de facilitar o uso e permitir a disponibilização desta técnica a pacientes do Sistema Único de Saúde. Estudo I: No primeiro estudo avaliamos se a disfunção de fibras nervosas finas periféricas está ligada a um mau funcionamento do sistema modulador descendente da dor (SMD) na FM. Métodos: Foi realizado um estudo exploratório no qual 41 mulheres com FM e 28 voluntárias saudáveis foram submetidas a testes psicofísicos que avaliaram a função de fibras sensitivas envolvidas na nocicepção. O teste quantitativo sensorial (QST) foi utilizado para medir o limiar perceptivo térmico (HTT), o limiar de dor térmica (HPT) e o limiar de tolerância à dor térmica (HPTo), bem como avaliar a mudança na Escala Numérica de Dor (NPS0-10) durante uma tarefa de modulação da dor condicionada (CPM-task). A algometria foi utilizada para determinar o limiar de pressão de dor (PPT). Escalas para avaliação de catastrofização, ansiedade, depressão e distúrbios do sono também foram aplicadas. O fator neurotrófico derivado do cérebro (BDNF) foi medido como um marcador de neuroplasticidade. Realizamos modelos de regressão linear multivariada por grupo (saudáveis e FM) para estudar a relação entre a função do SMD e sua relação com as medidas psicofísicas. Resultados: As amostras diferiram em seu perfil psicológico, e nas medidas psicofísicas, o grupo e pacientes com FM apresentou menor sensibilidade e limiares de dor. Na FM, mas não nos saudáveis, os modelos de regressão revelaram que o HTT estava relacionado ao BDNF e ao CPM-Task (Hotelling's Trace = 1,80, P<0,001, poder=0,94, R2=0,64). HTT foi correlacionado positivamente com a CPM-task (B = 0,98, P= 0,004, Partial-ƞ2=0,25), e ao HPT (B=1,61, P=0,008, parcial -ƞ2= 0,21). No entanto PPT não foi correlacionado com o HTT. Na FM a relação do BDNF com CPM-Task teve uma relação negativa (B=-0,04, P=0,043, parcial-ƞ2=0,12) e a HPT foi diretamente proporcional (B= - 0,08, P=0,03, parcial-ƞ2 = 0,14). O BDNF não influenciou no modelo. E os efeitos adversos relatados foram maiores no grupo ativo (17,8%) em comparação com o grupo sham (6,6%). Conclusão: A disfunção sensorial periférica está associada positivamente à disfunção do sistema modulatório descendente da dor e aos níveis séricos de BDNF na FM, o que não ocorre em indivíduos saudáveis. Estudo II: O segundo estudo teve como objetivo avaliar a eficácia do uso domiciliar de 60 sessões da ETCC-ativa e ETCC-simulada aplicadas sobre a área DLPFC esquerda, nas pacientes com diagnóstico de FM. Métodos: Foi realizado um ensaio clínico randomizado, duplo cego, em paralelo, controlado com ETCC-simulada em 20 mulheres com diagnóstico de fibromialgia. A estimulação foi realizada durante cinco dias consecutivos na semana, durante 30 min, com a intensidade de 2 mA, por 12 semanas, totalizando 60 sessões. As pacientes receberam treinamento para uso do equipamento especialmente desenvolvido para uso domiciliar e mantinham contato com o pesquisador responsável por meio de mensagem de texto diariamente. Os efeitos foram medidos por meio da escala visual de dor (EAV) durante o curso de 12 semanas de tratamento, bem como o uso de analgésicos e possíveis eventos adversos, diariamente. Foram avaliados os níveis de depressão, catastrofismo e capacidade funcional para tarefas diárias, QST para verificar limiar de dor e tolerância ao calor, PPT e dosagem dos níveis séricos de BDNF no início, após 30 sessões e no final do tratamento. Um modelo linear misto com efeitos fixos foi usado para comparar mudanças nos escores de dor na EAV ao longo do tratamento. Resultados: A ETCC ativa domiciliar reduziu os escores de dor pela EAV (p<0.001) quando comparado ao sham, com uma redução média de dor de 64% (p<0.001). Além disso, ETCC ativa reduziu significativamente a incapacidade relacionada a dor [B-PCP:S escore total (p=0.023);-ƞ2=0.61]. Também reduziu os escores nas medidas clínicas de depressão, catastrofismo e qualidade do sono [BDI-II, PCS e PSQI (p<0.05)]. No entanto, ETCC ativa aumentou os escores na algometria (PPT) e tolerância térmica (HPTo) (p<0.01). O BDNF não influenciou no modelo. Os efeitos adversos relatados foram maiores no grupo ativo (17,8%) em comparação com o grupo sham (6,6%). Conclusão: A ETCC para uso domiciliar mostrou-se segura e eficaz na redução da dor, incapacidade relacionada a dor, sintomas depressivos e catastróficos e redução do uso de analgésicos. O conjunto de dados desta tese sugere que em pacientes fibromiálgicas, o nível de disfunção do sistema modulador descendente da dor está relacionado ao nível de disfunção de fibras nervosas finas periféricas envolvidas na nocicepção. Além disso, a ETCC de longo prazo em fibromiálgicas foi eficaz na melhora dos sintomas disfuncionais relacionados à dor crônica e se mostrou adequada para uso domiciliar. / Introduction: Transcranial direct current stimulation (tDCS) is a noninvasive method of brain stimulation that modifies the resting potential of the neuronal membrane through a low intensity electrical current. It is a neuromodulatory technique to the therapeutic context of dysfunctions of the nervous system implicit in physiotherapy and neuropsychological disorders, with low cost, adverse effects and easy application. tDCS has been effective without a chronic fight process, including fibromyalgia (FM), in which the processes of disinhibition are cortical and infracortical, demonstrated by neurophysiological as intracortical facilitation and desinhibition, as well as reduction of the power of the systems descending pain modulators. In addition, studies have shown a severity of inhibition of central positive correlation with BDNF (Brain Derived Neurotrophic Factor) levels and seems to have some relation to the peripheral nociceptive pathways, as the areas of application of the stimulation depend on the primary motor cortex (M1) is the most studied target and the largest contingent of selection for the treatment of pain and motor reaction, while the dorsolateral prefrontal cortex (DLPFC) was effective in the treatment of depression and psychoaffective components in cases of patients with the chronic condition. Although tDCS has been successful in treating FM, its main limiter is a need for the service center for consecutive days as it has cumulative effect. In fact, the erasure of the sessions guaranteed the therapeutic effect of the ETCC. The application of measures on consecutive days motivated the study of its value when applied at the household level, in order to allow the large-scale treatment technique to be adopted in the Unified Health System. This is proved by two studies. The first objective is to examine whether a fine-fiber dysfunction that occurs in patients with FM is linked to an operation of the pain-modulating system. Neuropathy of long nerve fibers has been implicated by a descriptor of pain, neurophysiological and psychophysiological neurophysiology, as well as skin biopsy studies. However, this comparison was not associated with dysfunction in the descending pain system (DPMS) not on FM. Objective did the study explore the association of dysfunction of small fibers with the DPMS and other substitutes for nociceptive changes in FM. In the second, the term is a measure of long-term use of ETCC at household level in FM Study I: In this first study evaluating the presence of nerve and peripheral fiber failure, it is linked to the functioning of the descending pain modulator system (DPMS) in FM Methods: It was performed an exploratory study with 41 FM women and 28 healthy volunteers whose were evaluated in psychophysical tests that evaluated a function of sensory fibers involved in nociception. The quantitative sensory test (QST) was used to measure the Heat thermal threshold (HTT), the heat pain threshold (HPT) and the thermal pain tolerance (HPTo), as well as the numerical scale of pain (NPS0 -10 ) over a task of modulation of conditioned pain (CPM-task). Algometry was used to determine the pain pressure threshold (PPT). Scales for evaluation of catastrophic, anxiety, depression and sleep disorders were also applied. Brain-derived neurotrophic factor (BDNF) was measured as a marker of neuroplasticity. Multivariate linear regression models by group (health and FM) for a relationship between a descending modulatory system function and its relationship with psychophysical measures. Results: The samples differed in their psychological profile, and in the psychophysical measures, the group and the patients with FM had lower sensitivity and pain thresholds. At FM, regression models revealed that HTT was related to BDNF and CPM-Task (Hotelling's Trace = 1.80, P <0.001, power = 0.94, R2 = 0.64). HTT was positively correlated with a CPM task (B = 0.98, P = 0.004, partial-ƞ2 = 0.25), and HPT (B = 1.61, P = 0.008, partial -ƞ2 = 0.21) . However PPT was not correlated with HTT. In FM, the relationship of BDNF with CPM, a negative relation was found (B = -0.04, P = 0.043, partial- = 2 = 0.12) and HPT was proportionally (B = -0.08, P = 0.03, partial-ƞ2 = 0.14). BDNF did not influence the model. And the adverse effects reported were higher in the active group (17.8%) compared to the sham group (6.6%). Conclusion: Peripheral sensory dysfunction is positively associated with the modulating dysfunction of BDNF levels in FM, which does not occur in isolated individuals. Study II: The second study had the purpose of evaluating the home use of 60 sessions of atDCS and s-tDCS on a left DLPFC area in patients with FM. Methods: A randomized, double-blind, parallel-sham controlled study in 20 women with FM. Stimulation was performed for five consecutive days in the week for 30 min at the intensity of 2 mA for 12 weeks, totaling 60 sessions. Patients were trained to use equipment specially designed for home use and maintained contact with the researcher responsible through daily text message. The effects were measured through visual pain scale (VAS) daily during the course of 12 weeks of treatment, as well as the use of analgesics and possible adverse events daily. The levels of depression, catastrophism and disability for daily tasks were assessed. The QST was used to check pain threshold and tolerance to heat, an algometry was used to check pressure pain threshold (PPT) and blood collection was performed to evaluate serum BDNF levels at baseline, after 30 sessions and at the end of treatment. A Mixed Linear Model with fixed effects was used to compare changes in pain scores in VAS throughout the treatment. Results: Home-based tDCS reduced dairy pain VAS scores (p<0.001), with cumulative mean pain drop of 64% (p<0.001). Furthermore, active home-based tDCS reduced significantly disability due to pain [B-PCP:S total scores (p=0.023; partial-ƞ2=0.61]. And also reduced scores in clinical measures like depression scores, catastrophizing pain scores and sleep quality scores [BDI-II and PCS (p<0.05), PSQI (p<0.05)]. However, active homebased tDCS enhance scores in algometry (PPT) and heat pain tolerance (HPTo) (p<0.01). Conclusion: Home-based anodal tDCS applied over the DLPFC in FM had a baseline neuroplasticity-dependent reduction effect on pain. In addition, it improved the disability due to pain, depressive symptoms and pain catastrophizing. It reduced the analgesic use and increased pressure and heat pain tolerance.

Résumé : Introduction: À ce jour, notre compréhension des mécanismes neurophysiologiques responsables du développement d'une douleur chronique est encore relativement limitée. Il est proposé que certaines modifications dans l'efficacité des mécanismes endogènes d'inhibition descendante de la douleur pourraient contribuer à ce phénomène. Considérant l'importance de la neurotransmission monoaminergique dans les mécanismes descendants de modulation de la douleur, autant inhibiteur que facilitateur, nous émettons l'hypothèse que la persistance temporelle d'une douleur peut provoquer des modifications dans la fonctionnalité des deux systèmes majeurs (sérotoninergique et noradrénergique) sous-jacents à ces mécanismes de contrôle endogène, participant ainsi à la dynamique de développement et à la progression des états de douleur chronique à travers le temps. Objectif général: En utilisant une approche translationnelle, nous avons exploré l'association entre la fonctionnalité (centrale & périphérique) des systèmes de neurotransmission monoaminergique et l'efficacité des mécanismes descendants d’inhibition pendant le développement et la progression d'une douleur chronique. Résultats cliniques: D'une part, nos résultats répliquent plusieurs observations de la littérature ayant démontré une diminution de l'efficacité des mécanismes descendants d’inhibition de la douleur (à l'aide d'un paradigme de modulation conditionnée de la douleur; MCD) chez des sujets souffrant de douleur musculosquelettique chronique (sujets CP). Chez ces mêmes sujets, nous observons également une diminution des concentrations plasmatiques basales en noradrénaline (NA) et métanéphrine, lorsque comparés à des sujets sains (sujets PF). Pour tous les sujets testés (PF et CP), une association positive est mise en évidence entre l'efficacité de la MCD et les concentrations plasmatiques basales en NA et métanéphrine. Par conséquent, ces concentrations des catécholamines dans le plasma pourraient servir d'indicateurs moléculaires de l'efficacité latente de la MCD. Par ailleurs, aucune différence dans l'activité monoaminergique et aucune association avec l'efficacité de la MCD n'ont été observées au niveau du liquide céphalorachidien (LCR). Résultats précliniques: D'autre part, nous proposons un nouveau modèle de douleur à double atteinte chez le rongeur (i.e., induction initiale d'une douleur persistante [la 1ere atteinte] et activation subséquente des mécanismes descendants de modulation de la douleur à l'aide d'une douleur tonique [la 2e atteinte]). Ce paradigme expérimental nous permet ainsi d'évaluer l'efficacité des mécanismes descendants de modulation de la douleur chez les rongeurs en contexte de douleur chronique. Ainsi, nous mettons en évidence une diminution de la réponse comportementale à une douleur tonique (dans le test à la formaline), 28 jours après l'induction d'une douleur neuropathique (modèle de constriction chronique du nerf sciatique; CCI), lorsque comparés aux rats sham. Bien que cette diminution des comportements nociceptifs soit encore observable 168 jours après le début de la neuropathie, celle-ci semble tout de même s'amenuiser à travers le temps. Parallèlement, en l'absence de stimulation nociceptive tonique, une augmentation des concentrations en sérotonine et noradrénaline est observée au niveau central (i.e., dans le LCR) 12 jours après l'induction de la douleur neuropathique, avant de retourner ensuite à un niveau comparable à celui des rats sham au jour 28. Par ailleurs, la réponse comportementale observée au jour 28 est visible seulement dans un modèle de douleur neuropathique (CCI), et non lorsqu'une douleur inflammatoire est utilisée comme douleur persistante initiale. Conclusions: En contexte de douleur chronique, nos résultats chez l'humain confirment la présence de modifications dans l'efficacité des mécanismes descendants d’inhibition de la douleur, en plus de soutenir le concept émergent qui suggère que les différences dans l'efficacité de ceux-ci pourraient être associées à des différences individuelles dans certains processus périphériques (comme la relâche de catécholamines dans le sang), pouvant ultimement être impliquées dans la régulation cardiovasculaire. Par ailleurs, nos résultats chez le rongeur suggèrent que des changements dynamiques (spécifiques au type de douleur) dans l'efficacité des mécanismes descendants de modulation, ainsi que dans la fonctionnalité centrale des systèmes de neurotransmission monoaminergique, se produisent lors de la progression d'une douleur chronique. Dans son ensemble, cette thèse apporte de nouvelles informations au sujet des changements neurophysiologiques temporels au sein des mécanismes descendants de modulation de la douleur pouvant être impliqués dans le développement et la progression de la douleur chronique. / Abstract : Introduction: Hitherto, our understanding about the neurophysiological mechanisms responsible for the development of chronic pain is still relatively limited. It is suggested that modifications in the efficacy of endogenous pain inhibitory mechanisms could contribute to this phenomenon. Considering the importance of monoaminergic neurotransmission in descending pain modulation, either of inhibitory or facilitatory influence, we hypothesize that temporal persistence of pain can trigger modifications in the functionality of the two major systems (serotoninergic and noradrenergic) underlying these endogenous control mechanisms, thus participating in the development and progression of chronic pain states. General objective: Adopting a translational approach, we explored the association between the functionality (central & peripheral) of monoaminergic neurotransmission and the efficacy of descending inhibitory mechanisms during the development and progression of chronic pain. Clinical results: Our results replicate several observations emanating from the literature demonstrating a diminution in the efficacy of descending pain inhibitory mechanisms (using a conditioned pain modulation paradigm; CPM) in subjects with chronic musculoskeletal pain (CP subjects). In these CP subjects, we also highlight a reduction in basal plasma concentrations of noradrenaline and metanephrine, when compared with pain-free subjects (PF subjects). For all tested subjects (PF and CP subjects), a positive association is observed between CPM efficacy and basal plasma concentrations of noradrenaline and metanephrine. Therefore, basal plasma catecholamines concentrations could be used as molecular indicators of the latent CPM efficacy. Conversely, no difference in monoaminergic activity and no association with CPM efficacy are observed when looking at the molecular content of cerebrospinal fluid. Preclinical results: Here, we expose a new double-hit model of pain in rodents (i.e., initial induction of a persistent pain [the 1st hit] and subsequent activation of descending pain modulatory mechanisms with tonic pain [the 2nd hit]). This experimental paradigm allows us to evaluate the efficacy of decending pain modulation in rodents in the context of chronic pain. Interestingly, we detect a reduction in the behavioral response to tonic pain (in the formalin test), 28 days after the induction of neuropathic pain (chronic constriction injury model; CCI), when compared to sham rats. Even though this reduction in nociceptive behaviors is still present 168 days after neuropathy, the effect seems to wane down over time. Concomitantly, in absence of tonic nociceptive stimulation, an elevation in central concentrations (i.e., cerebrospinal fluid) in serotonin and noradrenaline is observed 12 days after the induction of neuropathic pain, before returning to sham levels on day 28. Moreover, the behavioral response described on day 28 is only observed in a neuropathic pain model (CCI), and absent when inflammatory pain is used as the initial pain. Conclusions: In the context of chronic pain, our results in humans confirm the advent of modifications in the efficacy of descending pain inhibitory mechanisms, while supporting the emerging concept suggesting that individual differences in these mechanisms may be associated with individual differences in peripheral processes (such as the release of catecholamines in plasma), that could ultimately be involved in cardiovascular control. Moreover, our results in rodents suggest that dynamic changes (specific to pain types) in the efficacy of descending pain modulation, as well as in the central functionality of monoaminergic neurotransmission, are present during the progression of chronic pain. Overall, this thesis provides novel information concerning temporal neurophysiological changes in descending pain modulatory mechanisms that may be involved in the development and progression of chronic pain states.

La douleur est une expérience multidimensionnelle comportant des aspects sensoriels, émotionnels et cognitifs. Il a été montré que cette expérience peut être modulée par des facteurs psychologiques ou des interventions cognitives comme l’attention, la distraction, l’hypnose ou les attentes. La tradition orientale suggère également que la pratique de la méditation pourrait avoir des effets analgésiques. D’un point de vue théorique, plusieurs mécanismes pourraient expliquer ces effets. Cependant, très peu d’études ont testé ces hypothèses. Les études présentées dans cette thèse avaient donc pour objectif d’examiner les mécanismes analgésiques de la méditation. Dans un premier temps, une étude psychophysique a été réalisée afin de comparer les réponses à la douleur entre des adeptes de la méditation Zen et des sujets contrôles, dans différentes conditions attentionnelles. Durant la condition attentionnelle de type « mindful », les adeptes de la méditation ont présenté une plus faible sensibilité à la douleur, des réponses attentionnelles à la douleur atypiques et une diminution de la perception de la douleur associée à l’entraînement à la méditation. Une deuxième étude a été réalisée en imagerie par résonance magnétique fonctionnelle (IRMf) avec des groupes de participants similaires. Dans une condition sans méditation, les adeptes de la méditation ont présenté de plus fortes réponses nociceptives dans les régions primaires de la douleur. Les régions cérébrales associées aux processus d’évaluation, à la mémoire et aux émotions ont quant à elles montré une diminution d’activité. De plus, cette diminution était plus importante chez les adeptes de la méditation les plus expérimentés et elle était associée à des évaluations de douleur plus faibles. Par ailleurs, des changements de connectivité fonctionnelle entre le cortex préfrontal et une région primaires de la douleur étaient associés à la sensibilité à la douleur chez les adeptes de la méditation. Finalement, une étude d’imagerie cérébrale structurale (publiée comme deux études séparées) a été réalisée pour examiner les différences d’épaisseur corticale entre les groupes, pour des régions associées à la douleur. Les adeptes de la méditation ont présenté une épaisseur plus importante de matière grise dans plusieurs régions associées à la douleur et l’attention. De plus, ces différences étaient associées à une mesure expérientielle de l’attention, à la sensibilité à la douleur et à l’expérience de méditation. Dans l’ensemble, ces résultats suggèrent que la méditation pourrait influencer la perception de la douleur par des changements fonctionnels et physiques dans le cerveau. De plus, le patron d’activation et la modulation de l’expérience paraissent uniques en comparaison à ceux d’autres interventions, ce qui suggère qu’un état de détachement et un focus mental favorisent la dissociation entre les aspects désagréables et sensoriels d’un stimulus nociceptif. / Pain is a multidimensional experience involving sensory, emotional and cognitive components. It is well known that mental factors or interventions such as attention, distraction, hypnosis or expectation can modulate painful experience. Traditional claims from the East suggest meditative practice may also have analgesic effects. Theoretically there are multiple avenues by which such practices could act, however little work has been done in this regard. The works presented in this dissertation were intended to address this paucity of research by contrasting pain perception in practicing meditators and non-meditating control participants. A psychophysical pain study was first conducted with practitioners of Zen meditation contrasting their responses to pain with control subjects during different attention conditions. Meditators were found to have lower baseline pain sensitivity, atypical attention-related pain responses and training-related reductions of pain ratings during mindful attention. A second study, with similar groups of subjects, employed functional magnetic resonance imaging (fMRI) during the perception of pain. In a non-meditative state, meditators were found to have stronger nociceptive-related brain activity in primary pain regions while simultaneously exhibiting reductions of activation in brain areas associated with appraisal, memory and emotion. These later effects were largest in the most advanced practitioners and were associated with the lowest pain ratings. Importantly, changes in functional connectivity between prefrontal cortex and a primary pain region predicted baseline pain sensitivity in the meditation group. Finally, a structural imaging experiment (published as two separate reports) was conducted to examine whether grey matter thickness may differ, in pain-relevant ways, between the groups. Meditators were found to have thicker regional grey matter in several pain and attention-related regions which corresponded both with an experiential measure of attention, pain sensitivity and meditation experience. Taken together these results suggest meditation may influence pain perception through functional as well as physical effects on the brain. The pattern of brain activity and experience modulation appears to be unique, when contrasted with previously studied interventions, and suggests that adopting a non-elaborative but focused mental stance may allow one to dissociate the bothersome qualities from the sensory aspects of a noxious stimulus.

Introdução: A osteoartrite de joelhos (KOA) apresenta alta prevalência, principalmente em mulheres. Com o envelhecimento da população esta prevalência irá aumentar. Os tratamentos conservadores apresentam limitada eficácia em expressivo número de pacientes no curso do tratamento . A cirurgia de protetização apresenta altos custos, possibilidade de complicações pós-operatórias graves e ainda que a correção anatômica seja perfeita, em torno de 20% dos pacientes persistem com dor crônica pós-operatória. Portanto, é preciso avançar no conhecimento dos mecanismos fisiopatológicos e estudar novas abordagens terapêuticas para agregar às existentes, visando melhor manejo da dor e para restabelecer a função de maneira mais efetiva. Estas questões motivaram três questões centrais que origiram os três estudos que compõem esta tese. Estudo I: No primeiro estudo avaliamos os mecanismos pelos quais há perpetuação da dor na KOA. Para responder a esta questão buscou respostas aos seguintes objetivos: I) Comparar se a função da via da dor inibitório descendente está associada com o estado de inibição no sistema corticospinal, indexado pelo potencial evocado motor (MEP) e o período de silêncio cortical (CSP) em pacientes com KOA e controles saudáveis. II) Determinar se há correlação entre as medidas de inibição intracortical (CSP, MEP) com alterações na escala de dor numérica (NPS 0-10) na KOA durante a tarefa de modulação condicionada de dor (CPM-task) considerando o efeito da capacidade funcional auto-relatada avaliada pelo Western Ontário and McMaster Universities Index (WOMAC) e uso de analgésicos. Métodos: Estudo transversal, foram incluídas 21 pacientes femininas com KOA e 10 controles saudáveis com idade entre 19 a 75 anos. Os parâmetros de excitabilidade do córtex motor (MEP e CSP) foram avaliados utilizando a estimulação magnética trasncraniana (EMT). Avaliação de dor e a incapacidade pelo WOMAC e a NPS (0-10) durante a CPM-task. Resultados: A média ajustada (DP) do CSP observada em pacientes com OA foi 23,43% menor do que em indivíduos saudáveis [54,54 (16,10) vs. 70,94 (22,87)], respectivamente (P = 0,01). A função do sistema modulador descendente de dor avaliado pela alteração do NPS (0-10) durante o CPM-task foi negativamente correlacionada com o parâmetro de excitabilidade cortical indexado pelo CSP (P = 0,001). O CSP foi negativamente correlacionado com a dor e incapacidade avaliada pelo índice WOMAC. Conclusão: Foi observado um sistema inibitório descendente de dor enfraquecido, corroborando com os achados em outras patologias de dor crônica. Estudo II O segundo estudo buscou determinar se na KOA, uma sessão de IMS (eletroestimulação intramuscular) ativa comparada com sham promove um efeito nos parâmetros de excitabilidade do córtex motor [MEP, inibição intracortical curta - SICI, facilitação intracortical (ICF) e CSP] e nas medidas de dor [limiar de dor a pressão (PPT); escala visual analógica de dor (VAS) e mudança na escala de dor numérica (NPS0-10) durante a CPM-task]. Esse estudo também se propôs a determinar se o fator neurotrófico derivado do cérebro (BDNF) sérico medeia o efeito desta estimulação no sistema cortico-espinhal, tal como avaliado pelo MEP e pelo PPT. Métodos: Foram incluídas 26 mulheres com KOA, com idade entre 50 a 75 anos. Elas foram divididas randomicamente para receber uma sessão de 30 minutos de IMS ativa (n = 13) ou IMS sham (n = 13) por meio de eletroestimulação com frequência de 2 Hz. As agulhas foram inseridas paravertebrais em nível da saída das raízes lombares de L1 a S2 e nos músculos cuja inervação corresponde a essas raízes e que sustentam a articulação do joelho (vasto medial, reto anterior, vasto lateral, tibial anterior e inserção da pata anserina). Os desfechos foram as medidas de dor (VAS, PPT, NPS durante CPM-task) e parâmetros de excitabilidade (MEP, CSP, SICI, ICF) realizados antes e imediatamente após a intervenção. Resultados: a IMS ativa comparado com sham diminuiu o MEP em 31,61% [intervalo de confiança (IC) 95%, 2,34-60,98]. Para os resultados secundários, IMS reduziu o ICF e aumentou o CSP. A IMS melhorou a dor relatada no VAS, o PPT e a pontuação do NPS (0-10) durante a CPM-task. O BDNF foi negativamente correlacionado com o PPT (r = 20,56). Conclusão: Obtivemos resultados demonstrando melhora da dor e reforço do sistema cortico-espinhal inibitório comparado ao tratamento sham com IMS. Estudo III O terceiro estudo buscou: 1) Avaliar se a utilização da ETCC (estimulação transcraniana de corrente contínua) combinada a IMS pode promover um resultado melhor de modulação da via cortico-espinhal de dor através da potenciação dos efeitos dos dois tratamentos; comparado a cada um deles isoladamente e ao tratamento sham. 2) Avaliar a capacidade da ETCC em reforçar o sistema inibitório descendente de dor e modular a excitabilidade neuronal através da VAS, PPT e NPS durante CPM-task. Além disso, avaliamos se o BDNF sérico poderia prever o efeito da terapia no final do tratamento. Métodos: 60 mulheres de 50 a 75 anos. Randomizadas em um de quatro grupos: ETCC+IMS, ETCC+IMS sham, ETCC sham+IMS, ETCC sham+IMS sham. Receberam 5 sessões de tratamento: ETCC anodal, lado contrário ao joelho acometido, 2mA, 30 min. IMS: estimulação com freqüência de 2Hz, 30 min; agulhas colocadas a 2cm de L1 á S2, nos músculos vasto medial, vasto lateral, reto anterior, tibial anterior e na inserção da pata anserina. Resultados: O a-tDCS + a-IMS mostrou os melhores resultados com diferença significativa na dor (VAS) [média (DP) relacionadas ao tratamento (pós e pré): 0.46 (0.04) vs. 6.32 (1.97); 95%CI -5.42 (-8.24 to -4.36), p=.003] e funcionalidade. Esse resultado iniciou na primeira sessão e manteve-se ao longo do estudo. A-tDCS+a-IMS foi o único capaz de modificar o sistema inibitório descendente de dor. Conclusão: Obtivemos melhora da dor e capacidade funcional com IMS, ETCC e ETCC+IMS. Mas somente o grupo de tratamento ETCC+IMS demonstrou capacidade de modificação do sistema inibitório descendente de dor. / Background: Knee osteoarthritis (KOA) has a high prevalence, especially in women. With the aging of the population this prevalence will increase. Conservative treatments have limited efficacy in expressive number of patients in the course of the treatment. The total knee replacement surgery presents high costs, possibility of serious postoperative complications and although the anatomical correction is perfect, around 20% persist with chronic postoperative pain. Therefore, it’s necessary to advance in the knowledge of pathophysiological mechanisms and to study new therapeutic approaches to add to the existing ones, aiming to better manage pain and to restore function more effectively. These questions motivated three central questions that originated the three studies that compose this thesis. Study I In the first study we evaluated the mechanisms by which there is perpetuation of pain in knee osteoarthritis and to answer this question sought to answer the following objectives: I) To compare if the function of the descending inhibitory pain pathway is associated with the state of inhibition in the corticospinal system, indexed by the motor evoked potential (MEP) and the cortical silent period (CSP) in patients with KOA and healthy controls. II) To determine if there is a correlation between the intracortical inhibition measures (CSP, MEP) with changes in the numerical pain scale (NPS 0-10) in the KOA during the task of conditioned pain modulation (CPM-task) considering the effect of the self-reported function evaluated by the Western Ontario and McMaster Universities Index (WOMAC) and the use of analgesics. Methods: A cross-sectional study included 21 female patients with KOA and 10 healthy controls aged 19-75 years old. Motor cortex excitability parameters (MEP and CSP) were assessed using transcranial magnetic stimulation (TMS). Pain assessment and disability by WOMAC and NPS (0-10) during the CPM-task. Results: The adjusted mean (SD) of CSP observed in patients with OA was 23.43% lower than in healthy subjects [54,54 (16,10) vs 70.94 (22.87)], respectively (P = 0.01). The function of the descending pain modulatory system evaluated by the NPS (0-10) change during the CPM-task was negatively correlated with the cortical excitability parameter indexed by CSP (P = 0.001). CSP was negatively correlated with pain and disability assessed by the WOMAC index. Conclusion: It was observed a descending pain inhibitory system weakened, corroborating the findings of other chronic pain conditions. Study II The second study sought to determine if one active IMS session compared to sham promoted an effect on motor cortex excitability (MEP, short intracortical inhibition - SICI, intracortical facilitation (ICF) and CSP and in the pain measures [pressure pain threshold (PPT); Visual analogue pain scale (VAS) and numerical pain scale change (NPS0-10) during the CPM-task]. This study also aimed to determine whether serum brain-derived neurotrophic factor (BDNF) mediates the effect of this stimulation on the cortico-spinal system, as assessed by MEP and PPT. Methods: Twenty-six women with KOA, aged 50-75 years old, were included. They were randomly divided to receive a 30-minute session of active IMS (n = 13) or IMS sham (n = 13) by electrostimulation with a frequency of 2 Hz. The needles were inserted paravertebral at the level of the lumbar roots exit from L1 to S2 and in the muscles whose innervation corresponds to these roots and which support the knee joint (vastus medialis, rectus anterior, vastus lateral, tibialis anterior and insertion of the anserine paw). The outcomes were pain measures (VAS, PPT, NPS during CPM-task) and excitability parameters (MEP, CSP, SICI, ICF) performed before and immediately after the intervention. Results: the active IMS compared with sham decreased the MEP by 31.61% [confidence interval (CI) 95%, 2.34-60.98]. For the secondary outcomes, IMS reduced ICF and increased CSP. IMS improved pain reported in VAS, PPT, and NPS score (0-10) during the CPM-task. BDNF was negatively correlated with PPT (r = 20.56). Conclusion: We obtained results demonstrating improvement of pain and enhancement of the inhibitory corticospinal system compared to sham treatment with IMS. Study III The third study aimed to: 1) Evaluate if the use of the combined tDCS (transcranial direct current stimulation) to IMS can promote a better result of modulation of the corticospinal pain pathway through the potentiation of the effects of the two treatments; compared to each of them alone, and with the sham treatment. 2) To evaluate the ability of the tDCS to strengthen the descending inhibitory pain system and to modulate neuronal excitability through VAS, PPT and NPS during CPM-task. In addition, we evaluated whether serum BDNF could predict the effect of therapy at the end of treatment. Methods: 60 women aged 50 to 75 years old. Randomized in one of four groups: tDCS + IMS, tDCS + IMS sham, tDCS sham + IMS, tDCS sham + IMS sham. They received 5 sessions of treatment: anodal tDCS, opposite side to affected knee, 2mA, 30 min. IMS: stimulation with frequency of 2Hz, 30 min; needles placed at 2 cm from L1 to S2, in the vastus medialis, vastus lateralis, rectus anterior, tibialis anterior and insertion of the anserine paw. Results: a-tDCS + a-IMS showed the best results with significant difference in pain (VAS) [mean (SD) related to treatment (post and pre): 0.46 (0.04) vs. 6.32 (1.97); 95% CI -5.42 (-8.24 to -4.36), p = .003] and functionality. This result started in the first session and was maintained throughout the study. A-tDCS + a-IMS was the only one able to modify the descending inhibitory pain system. Conclusion: We achieved improved pain and functional capacity with IMS, tDCS and tDCS + IMS. But only the tDCS + IMS treatment group demonstrated ability to modify the descending inhibitory pain system.

Os objetivos do presente trabalho foram: 1) analisar a distribuição das fibras nervosas autonômicas na articulação temporomandibular (ATM) do rato, através da detecção de tirosina hidroxilase (TH), neuropeptídeo Y (NPY) e peptídeo intestinal vasoativo (VIP); 2) realizar um estudo topográfico ultra-estrutural das fibras e terminações nervosas autonômicas na ATM do rato; 3) determinar o padrão de ativação neuronal no complexo nuclear trigeminal e, em centros nervosos moduladores da dor, durante a vigência de monoartrite no complexo articular temporomandibular (CATM) do rato. Para o primeiro propósito o método imunoistoquímico, para a detecção simultânea de TH, NPY e VIP, foi executado em ATMs que apresentavam as seguintes condições: inervação intacta ou desprovida de inervação simpática e/ou parassimpática. Para o segundo propósito aliamos o tratamento prévio com 5-hidroxidopamina, para evidenciação de terminações nervosas simpáticas, com a remoção cirúrgica do gânglio ótico, para a visualização das fibras e terminações nervosas parassimpáticas em degeneração, em seguida analisamos as ATMs ao microscópio eletrônico de transmissão. O terceiro propósito foi obtido induzindo-se monoartrite (fase aguda, crônica e crônica ativa) no CATM e, verificando a expressão de Fos, um marcador de ativação neuronal, no complexo nuclear sensorial trigeminal e nos principais centros nervosos moduladores da dor, situados no tronco encefálico (substância cinzenta periaqueductal- PAG; área rostral ventromedial da medula oblonga- RVM; locus coeruleus- LC; área caudal ventrolateral da medula oblonga- CVLM; núcleo do trato solitário- NTS e; núcleo reticular ventral-NRV). Verificamos que as ATMs desprovidas de inervação simpática apresentam exclusivamente uma pequena quantidade de fibras nervosas VIP-IR, ao passo que aquelas desprovidas de inervação parassimpática mostram uma grande quantidade de fibras nervosas TH/NPY-IR e TH/NPY/VIP-IR. As fibras e terminações nervosas autonômicas foram observadas em vasos sanguíneos ou isoladas no tecido conjuntivo, especialmente na membrana sinovial. No que se refere à expressão de Fos, constatamos que o subnúcleo caudal do núcleo do tracto espinal do nervo trigêmeo (Sp5C) e a PAG apresentaram um aumento bilateral significante na expressão de Fos durante todas as fases da monoartrite induzida no CATM. Todavia, RVM, LC, CVLM, NTS apresentaram uma quantidade de neurônios Fos-IR significativamente aumentada, de ambos os lados, apenas quando o CATM estava sob vigência de monoartrite na fase aguda e crônica ativa. Concluímos que: 1) a ATM mostra-se densamente inervada por fibras nervosas simpáticas (TH/NPY-IR e TH/NPY/VIP-IR) e, por uma discreta quantidade de fibras nervosas parassimpáticas (VIP-IR), ambas predominantemente associadas com vasos sanguíneos; 2) o Sp5C e a PAG, mostra-se intensamente ativados em todas as fases da monoartrite no CATM, ao passo que a maioria dos centros nervosos moduladores da dor apresentam uma quantidade aumentada de neurônios imunoarreativos ao marcador de ativação neuronal, Fos, apenas durante as fases aguda e crônica ativa dessa monoartrite. / The goals of the present study were: 1) to analyse the distribution of autonomic nerve fibers in the rat temporomandibular joint (TMJ) under normal conditions using immunofluorescence method to detect tirosyne hydroxylase (TH), neuropetide Y (NPY) and vasoactive intestinal polypeptide (VIP); 2) to verify the detailed distribution of autonomic nerve fibers in the rat temporomandibular joint by transmission electron microscopy; 3) to determine the neuronal activation pattern in the trigeminal system and in the pain modulation centers during monoarthritis induced in the rat temporomandibular joint complex (TMJC). For the first purpose, histologic sections from TMJs with intact innervation or with surgical sympatectomy and/or parasympathectomy were submitted to simultaneous detection of TH, NPY and VIP. For the second purpose, 5-hydroxidopamine treatment to detect sympathetic nerve endings was combined with surgical parasympatectomy of the otic ganglion to detect degenerated parasympathetic nerve endings in the rat TMJC, by transmission electron microscopy. For the last purpose, monoarthritis (acute, chronic and chronic-active phases) was induced in the TMJC and histologic sections from the brain stem were submitted to immunodetection of Fos protein in the trigeminal system and in the pain modulation centers (periqueductal gray matter - PAG; rostroventromedial medulla - RVM; locus coeruleus- LC; caudal ventrolateral medulla- CVLM; nucleus of the solitary tract - NTS; ventral reticular nucleus - VRN). The most important results demonstrated that the TMJC showed a discrete parasympathetic innervation (VIP-IR), while the sympathetic innervation was dense and characterized by TH-/NPY-/VIP-IR or TH-/NPY-IR nerve fibers. Autonomic nerve fibers were mainly noted associated to blood vessels and occasionally disperse in the synovial membrane. Fos-IR neurons showed significant bilateral increase in the spinal trigeminal caudal subnucleus and PAG during arthritis evolution. On the other hand, RVM, LC, CVLM and NTS only showed significant increase of Fos-IR neurons during the acute and chronic-active phases of monoarthritis. The main conclusions were: 1) the TMJC shows a dense sympathetic innervation (TH/NPY-IR or TH-/NPY-/VIP-IR) and discrete parasympathetic innervation (VIP-IR), both associated mainly to blood vessels; 2) most modulation pain centers are activated principally during acute and chronic-active arthritis, while the spinal trigeminal caudal subnucleus and PAG showed continuous activation during all phases of arthritis.

Doenças do neurônio motor (DNM) representam um grupo de doenças que cursam com fraqueza muscular progressiva e inexorável, e o manejo clínico é baseado no controle dos sintomas. Estes doentes sofrem de acometimentos motores e não motores intensos e de evolução progressiva. Entretanto, além dos sintomas motores, de humor e de déficits cognitivos, uma caracterização mais profunda de sintomas não- motores nesses doentes raramente foi relatada. Este estudo transversal objetivou descrever os sintomas não motores na DMN e seu impacto na qualidade de vida e no estado funcional, com foco na dor e alterações sensoriais. Oitenta doentes (31 mulheres, 55,7 ± 12,9 anos) com DNM foram submetidos a exame clínico extenso, avaliação de dor (questionário de dor McGill, Inventário breve de dor, questionário douleur neuropathique-4), avaliação psicofísica [teste quantitativo da sensibilidade (TQS) e modulação condicionada da dor (MCD)], avaliações de humor e catastrofismo, e foram comparados com controles saudáveis (CS) pareados por sexo e idade. Dor crônica (presente a maior parte dos dias por mais de três meses) foi presente em 46% dos doentes (escala numérica da dor = 5,18 ± 2,0). A dor de origem musculo- esquelética ocorreu em 40,5% e foi localizada principalmente na região da cabeça/pescoço (51%) e da região lombar (35%). A dor neuropática não presente nesta amostra. Comparado aos CS, os doentes com DNM apresentaram menor limiar de detecção de frio (p < 0,002) e valores de MCD significativamente menores (4,9 ± 0,2% vs. 22,1 ± 0,2%, p = 0,012). Os resultados do TQS/MCD não diferiram entre os doentes com DNM com e sem dor. A intensidade da dor foi correlacionada estatisticamente com ansiedade, depressão e catastrofismo, e os escores de espasticidade foram correlacionados inversamente com a MCD (rho = -0,30, p = 0,026). A dor é um sintoma frequentemente relatado por doentes com DNM. Alterações somatossensoriais e de MCD existem em DNM e podem estar relacionadas com a natureza neurodegenerativa da doença. Estudos adicionais devem investigar formas de melhor quantificar estas alterações e explorar estratégias de tratamento mais apropriadas para o seu controle / Motor neuron disorders (MNDs) represent a group of diseases that curse with inexorable muscle weakness and medical management is based on symptom control. These patients suffer from intense motor and non-motor progressive symptoms. However, apart from motor symptoms, mood and cognitive impairments, deeper characterization of non-motor symptoms in these patients have been rarely reported. This cross-sectional study aimed to describe non-motor symptoms in MND and their impact on quality of life and functional status, with a focus on clinical pain and sensory changes. Eighty patients (31 females, 55.7±12.9 years old) with MND underwent a extensive clinical examination, pain (McGill pain questionnaire, brief pain inventory, douleur neuropathique-4), psychophysics [quantitative sensory testing (QST) and conditioned pain modulation (CPM)], mood and catastrophizing assessments, and were compared to sex- and age-matched healthy controls (HC). Chronic pain (present on most days for more than three months) was present in 46% of patients (numerical visual scale=5.18±2.0). Pain of musculoskeletal origin occurred in 40.5% and was mainly located in the head/neck (51%) and lower back (35%). Neuropathic pain was not present in this sample. Compared to HC, MND patients had a lower cold detection threshold (p < 0.002), and significantly lower CPM scores (4.9±0.2% vs. 22.1±0.2%, p=0.012). QST/CPM results did not differ between MND patients with and without pain. Pain intensity was statistically correlated with anxiety, depression, and catastrophism, and spasticity scores were inversely correlated with CPM (rho=-0.30, p=0.026). Pain is frequently reported by patients with MNDs. Somatosensory and CPM changes exist in MNDs and may be related to the neurodegenerative nature of the disease. Further studies should investigate ways to better quantify these changes and explore the treatment strategies most appropriated for their control

Doenças do neurônio motor (DNM) representam um grupo de doenças que cursam com fraqueza muscular progressiva e inexorável, e o manejo clínico é baseado no controle dos sintomas. Estes doentes sofrem de acometimentos motores e não motores intensos e de evolução progressiva. Entretanto, além dos sintomas motores, de humor e de déficits cognitivos, uma caracterização mais profunda de sintomas não- motores nesses doentes raramente foi relatada. Este estudo transversal objetivou descrever os sintomas não motores na DMN e seu impacto na qualidade de vida e no estado funcional, com foco na dor e alterações sensoriais. Oitenta doentes (31 mulheres, 55,7 ± 12,9 anos) com DNM foram submetidos a exame clínico extenso, avaliação de dor (questionário de dor McGill, Inventário breve de dor, questionário douleur neuropathique-4), avaliação psicofísica [teste quantitativo da sensibilidade (TQS) e modulação condicionada da dor (MCD)], avaliações de humor e catastrofismo, e foram comparados com controles saudáveis (CS) pareados por sexo e idade. Dor crônica (presente a maior parte dos dias por mais de três meses) foi presente em 46% dos doentes (escala numérica da dor = 5,18 ± 2,0). A dor de origem musculo- esquelética ocorreu em 40,5% e foi localizada principalmente na região da cabeça/pescoço (51%) e da região lombar (35%). A dor neuropática não presente nesta amostra. Comparado aos CS, os doentes com DNM apresentaram menor limiar de detecção de frio (p < 0,002) e valores de MCD significativamente menores (4,9 ± 0,2% vs. 22,1 ± 0,2%, p = 0,012). Os resultados do TQS/MCD não diferiram entre os doentes com DNM com e sem dor. A intensidade da dor foi correlacionada estatisticamente com ansiedade, depressão e catastrofismo, e os escores de espasticidade foram correlacionados inversamente com a MCD (rho = -0,30, p = 0,026). A dor é um sintoma frequentemente relatado por doentes com DNM. Alterações somatossensoriais e de MCD existem em DNM e podem estar relacionadas com a natureza neurodegenerativa da doença. Estudos adicionais devem investigar formas de melhor quantificar estas alterações e explorar estratégias de tratamento mais apropriadas para o seu controle / Motor neuron disorders (MNDs) represent a group of diseases that curse with inexorable muscle weakness and medical management is based on symptom control. These patients suffer from intense motor and non-motor progressive symptoms. However, apart from motor symptoms, mood and cognitive impairments, deeper characterization of non-motor symptoms in these patients have been rarely reported. This cross-sectional study aimed to describe non-motor symptoms in MND and their impact on quality of life and functional status, with a focus on clinical pain and sensory changes. Eighty patients (31 females, 55.7±12.9 years old) with MND underwent a extensive clinical examination, pain (McGill pain questionnaire, brief pain inventory, douleur neuropathique-4), psychophysics [quantitative sensory testing (QST) and conditioned pain modulation (CPM)], mood and catastrophizing assessments, and were compared to sex- and age-matched healthy controls (HC). Chronic pain (present on most days for more than three months) was present in 46% of patients (numerical visual scale=5.18±2.0). Pain of musculoskeletal origin occurred in 40.5% and was mainly located in the head/neck (51%) and lower back (35%). Neuropathic pain was not present in this sample. Compared to HC, MND patients had a lower cold detection threshold (p < 0.002), and significantly lower CPM scores (4.9±0.2% vs. 22.1±0.2%, p=0.012). QST/CPM results did not differ between MND patients with and without pain. Pain intensity was statistically correlated with anxiety, depression, and catastrophism, and spasticity scores were inversely correlated with CPM (rho=-0.30, p=0.026). Pain is frequently reported by patients with MNDs. Somatosensory and CPM changes exist in MNDs and may be related to the neurodegenerative nature of the disease. Further studies should investigate ways to better quantify these changes and explore the treatment strategies most appropriated for their control

Women exhibit greater habituation to painful stimuli than men. The neural mechanism underlying this sex difference is unknown. However, pain habituation has been associated with pain-evoked activity of the subgenual anterior cingulate cortex (sgACC), implicating a connection between the sgACC and the descending pain antinociceptive system. Therefore, the thesis hypothesis was that women have stronger connectivity than men between the sgACC and the descending antinociceptive system. Healthy subjects provided informed consent. 3T MRI images included anatomical diffusion-weighted imaging for structural connectivity analyses (SC) with probabilistic tractography and resting-state functional images for functional connectivity (FC) analyses. Women had stronger sgACC FC with nodes of the descending pain modulation system (raphe, PAG) and the medial thalamus. In contrast, men had stronger sgACC FC with nodes of the salience/attention network (anterior insula, TPJ) and stronger sgACC SC with the hypothalamus. These findings implicate a mechanism for pain habituation and its associated sex differences.

La douleur est une expérience multidimensionnelle comportant des aspects sensoriels, émotionnels et cognitifs. Il a été montré que cette expérience peut être modulée par des facteurs psychologiques ou des interventions cognitives comme l’attention, la distraction, l’hypnose ou les attentes. La tradition orientale suggère également que la pratique de la méditation pourrait avoir des effets analgésiques. D’un point de vue théorique, plusieurs mécanismes pourraient expliquer ces effets. Cependant, très peu d’études ont testé ces hypothèses. Les études présentées dans cette thèse avaient donc pour objectif d’examiner les mécanismes analgésiques de la méditation. Dans un premier temps, une étude psychophysique a été réalisée afin de comparer les réponses à la douleur entre des adeptes de la méditation Zen et des sujets contrôles, dans différentes conditions attentionnelles. Durant la condition attentionnelle de type « mindful », les adeptes de la méditation ont présenté une plus faible sensibilité à la douleur, des réponses attentionnelles à la douleur atypiques et une diminution de la perception de la douleur associée à l’entraînement à la méditation. Une deuxième étude a été réalisée en imagerie par résonance magnétique fonctionnelle (IRMf) avec des groupes de participants similaires. Dans une condition sans méditation, les adeptes de la méditation ont présenté de plus fortes réponses nociceptives dans les régions primaires de la douleur. Les régions cérébrales associées aux processus d’évaluation, à la mémoire et aux émotions ont quant à elles montré une diminution d’activité. De plus, cette diminution était plus importante chez les adeptes de la méditation les plus expérimentés et elle était associée à des évaluations de douleur plus faibles. Par ailleurs, des changements de connectivité fonctionnelle entre le cortex préfrontal et une région primaires de la douleur étaient associés à la sensibilité à la douleur chez les adeptes de la méditation. Finalement, une étude d’imagerie cérébrale structurale (publiée comme deux études séparées) a été réalisée pour examiner les différences d’épaisseur corticale entre les groupes, pour des régions associées à la douleur. Les adeptes de la méditation ont présenté une épaisseur plus importante de matière grise dans plusieurs régions associées à la douleur et l’attention. De plus, ces différences étaient associées à une mesure expérientielle de l’attention, à la sensibilité à la douleur et à l’expérience de méditation. Dans l’ensemble, ces résultats suggèrent que la méditation pourrait influencer la perception de la douleur par des changements fonctionnels et physiques dans le cerveau. De plus, le patron d’activation et la modulation de l’expérience paraissent uniques en comparaison à ceux d’autres interventions, ce qui suggère qu’un état de détachement et un focus mental favorisent la dissociation entre les aspects désagréables et sensoriels d’un stimulus nociceptif. / Pain is a multidimensional experience involving sensory, emotional and cognitive components. It is well known that mental factors or interventions such as attention, distraction, hypnosis or expectation can modulate painful experience. Traditional claims from the East suggest meditative practice may also have analgesic effects. Theoretically there are multiple avenues by which such practices could act, however little work has been done in this regard. The works presented in this dissertation were intended to address this paucity of research by contrasting pain perception in practicing meditators and non-meditating control participants. A psychophysical pain study was first conducted with practitioners of Zen meditation contrasting their responses to pain with control subjects during different attention conditions. Meditators were found to have lower baseline pain sensitivity, atypical attention-related pain responses and training-related reductions of pain ratings during mindful attention. A second study, with similar groups of subjects, employed functional magnetic resonance imaging (fMRI) during the perception of pain. In a non-meditative state, meditators were found to have stronger nociceptive-related brain activity in primary pain regions while simultaneously exhibiting reductions of activation in brain areas associated with appraisal, memory and emotion. These later effects were largest in the most advanced practitioners and were associated with the lowest pain ratings. Importantly, changes in functional connectivity between prefrontal cortex and a primary pain region predicted baseline pain sensitivity in the meditation group. Finally, a structural imaging experiment (published as two separate reports) was conducted to examine whether grey matter thickness may differ, in pain-relevant ways, between the groups. Meditators were found to have thicker regional grey matter in several pain and attention-related regions which corresponded both with an experiential measure of attention, pain sensitivity and meditation experience. Taken together these results suggest meditation may influence pain perception through functional as well as physical effects on the brain. The pattern of brain activity and experience modulation appears to be unique, when contrasted with previously studied interventions, and suggests that adopting a non-elaborative but focused mental stance may allow one to dissociate the bothersome qualities from the sensory aspects of a noxious stimulus.